Krilogy Financial
RARE icon

Krilogy Financial’s Ultragenyx Pharmaceutical RARE Stock Holding History

Krilogy Financial’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-11,941
Closed -$399K – 1162
2026
Q2 		$399K Buy
+11,941
New +$297K 0.01% 718
2018
Q2 		– Sell
-100
Closed -$5K – 513
2018
Q1 		$5K Hold
100
– – ﹤0.01% 602
2017
Q4 		$5K Hold
100
– – ﹤0.01% 604
2017
Q3 		$5K Hold
100
– – ﹤0.01% 657
2017
Q2 		$6K Buy
+100
New +$6.02K ﹤0.01% 582

Other funds holding RARE

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Pinnacle Associates
Pinnacle Associates New York $8.92B AUM 43.91% 1-Year Est. Return
Harbor Capital Advisors
Harbor Capital Advisors Chicago, Illinois $1.48B AUM 30.88% 1-Year Est. Return
Apollon Wealth Management
Apollon Wealth Management Mount Pleasant, South Carolina $8.72B AUM 23.07% 1-Year Est. Return
L. Roy Papp & Associates
L. Roy Papp & Associates Phoenix, Arizona $981M AUM 26.21% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Davenport & Co
Davenport & Co Richmond, Virginia $19.9B AUM 12.67% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return
Versant Capital Management
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
Sterling Capital Management
Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

Krilogy Financial's RARE Position: Q3 2026 in Review

Krilogy Financial sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2026, closing a stake of 11,941 shares — an estimated $399K sold.

Krilogy Financial first reported a position in RARE in Q2 2017 and held it in 5 quarters. The position peaked at $399K in Q2 2026. 24 funds tracked by Wall St. Rank hold RARE as of Q3 2026.

  • Krilogy Financial reported no remaining Ultragenyx Pharmaceutical position as of Q3 2026 after selling out during the quarter.
  • Krilogy Financial sold 11,941 Ultragenyx Pharmaceutical shares in Q3 2026, an estimated $399K.
  • Krilogy Financial first reported a position in Ultragenyx Pharmaceutical in Q2 2017 and held it in 5 quarters.
  • Krilogy Financial's Ultragenyx Pharmaceutical position peaked at $399K in Q2 2026.
  • 24 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2026.

Based on Krilogy Financial's 13F filing for Q3 2026, filed 13 Oct 2026.